Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study of Trifluridine/ Tipiracil Plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04511039
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:19.203889+00:00
Published At
2026-03-02T00:00:00+00:00
Record Updated At
2026-03-02
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Advanced Malignant Solid Neoplasm", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A", "Locally Advanced Colorectal Carcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Metastatic Colorectal Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-03-02"
protocolSection.identificationModule.nctId
"NCT04511039"
protocolSection.identificationModule.officialTitle
"A Phase I Study of Trifluridine/ Tipiracil Plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Advanced Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Clinical Stage III Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Clinical Stage IV Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A (protocolSection.conditionsModule.conditions)
  • Locally Advanced Colorectal Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Colorectal Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Pathologic Stage III Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage III Colorectal Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Colorectal Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Colorectal Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIC Colorectal Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Colorectal Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IVA Colorectal Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IVB Colorectal Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IVC Colorectal Cancer AJCC v8 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.